IRADIMED Posts Record Q4, Raises Dividend and Outlines 2026 Rollout for New MRI Pump

Management signals a broad 3870 pump rollout starting early 2026, with revenue expected to skew to the second half.

Overview

Q4 2025 revenue rose 17% to $22.7 million with net income of $6.4 million, and full‑year revenue reached $83.8 million with GAAP diluted EPS of $1.75.
2026 guidance calls for $91.0 million to $96.0 million in revenue and GAAP EPS of $1.90 to $2.05, with a general 3870 sales release planned for April and initial shipments of roughly 100 to 130 pump channels as bookings build in Q2.
IRADIMED declared a higher quarterly cash dividend of $0.20 per share payable March 6, 2026.
For Q1 2026, the company projects revenue of $21 million to $22 million and diluted EPS of $0.44 to $0.48.
The quarter marked an 18th straight record revenue period as the company delivered an initial 23 3870 systems in December, targets 10% to 14% higher pump deal ASPs and a large replacement market, and saw shares trade up nearly 10% after the report.